NCT05159440View on ClinicalTrials.gov

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2025

Conditions
Advanced Solid TumorGastric CancerPancreas CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

TORL-2-307-MAB

monoclonal antibody

Trial Locations (8)

13620

Seoul National University Bundang Hospital, Seoul

46804

Fort Wayne Medical Oncology and Hematology, Fort Wayne

63110

Washington University School of Medicine-Siteman Cancer Center, St Louis

90095

UCLA - JCCC Clinical Research Unit, Los Angeles

90505

Torrance Memorial Medical, Torrance

92835

Providence St. Jude Medical Center, Fullerton

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

lead

TORL Biotherapeutics, LLC

INDUSTRY